Cargando…

Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant: SARS-CoV-2 Vaccine as a Potential Trigger

Allogeneic hematopoietic stem cell transplant (AHSCT) recipients are at a risk of developing immune-mediated tissue damage from activation of the donor’s immunocompetent T cells by the recipient’s normally expressed antigens, a phenomenon called graft-versus-host disease (GVHD). With the emergence o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azem, Amin, Ajmal, Zainub, Raval, Mihir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262658/ https://www.ncbi.nlm.nih.gov/pubmed/35812599 http://dx.doi.org/10.7759/cureus.25738

Ejemplares similares

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience
por: Hashmi, Hamza, et al.
Publicado: (2020)

Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation
por: Martin, Paul J., et al.
Publicado: (2022)

Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation
por: Miyata, Masahiro, et al.
Publicado: (2023)

Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic
por: Devine, Steven M., et al.
Publicado: (2023)

Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
por: Chiesa, Robert, et al.
Publicado: (2022)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades
por: Nishiwaki, Satoshi, et al.
Publicado: (2022)

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant
por: Pérez-Valencia, Amanda Isabel, et al.
Publicado: (2022)

Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation
por: Kanaan, Sami B., et al.
Publicado: (2023)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023)

Prognostic Value of Hematogones in Patients With Hematopoietic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
por: Mori, Hirotaka, et al.
Publicado: (2023)

Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation
por: Ren, Xiying, et al.
Publicado: (2021)

Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
por: Masetti, Riccardo, et al.
Publicado: (2023)

Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure
por: Sabulski, Anthony, et al.
Publicado: (2021)

Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease
por: Akahoshi, Yu, et al.
Publicado: (2022)

MicroRNA serum profiles and chronic graft-versus-host disease
por: Reikvam, Håkon, et al.
Publicado: (2022)

An Unusual Presentation of Nocardiosis in an Allogeneic Transplant Recipient
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Treatment of allosensitized patients receiving allogeneic transplantation
por: Ciurea, Stefan O., et al.
Publicado: (2021)

Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival
por: Pidala, Joseph, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
por: van Lier, Yannouck F., et al.
Publicado: (2023)

Evidence-based, Skin-directed Treatments for Cutaneous Chronic Graft-versus-host Disease
por: Kim, Yoo Jung, et al.
Publicado: (2019)

Genetic variants associated with inflammatory bowel disease and gut graft-versus-host disease
por: Martin, Paul J., et al.
Publicado: (2021)

Prediction of outcomes after second-line treatment for acute graft-versus-host disease
por: Vo, Phuong, et al.
Publicado: (2022)

Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
por: Robin, Marie, et al.
Publicado: (2022)

Graft Versus Host Disease After Intestinal Transplantation: A Single-center Experience
por: Kaufman, Stuart S., et al.
Publicado: (2021)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft‐versus‐host disease
por: Pratta, Michael, et al.
Publicado: (2022)

Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease
por: Shrestha, Pradeep, et al.
Publicado: (2023)

A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation
por: Hudspeth, Michelle, et al.
Publicado: (2022)

Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
por: Magenau, John M., et al.
Publicado: (2021)

The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society
por: Alfred, Arun, et al.
Publicado: (2017)

CLINICAL OUTCOMES IN LUNG TRANSPLANT RECIPIENTS WITH SARS-COV-2
por: BOTROS, MENA, et al.
Publicado: (2021)

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
por: Cutler, Corey, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9knnepvi6riv9vd7jjnj72mu4j